RxDoctor Payments Data

Charles Gallegos

Family · Albuquerque, NMNPI 1912050089

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (42.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by United Therapeutics Corporation at 47.0% of the total. Reporting peaked in 2021 at $4,249 and has fallen 67.5% since, to $1,381 in 2025. Among family clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,991in general payments, 2019–2025

Across 71 payments — averaging $140.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$5K
  • Johnson & Johnson$3K
  • Bayer$1K
  • Actelion Pharmaceuticals US, Inc.$1K
  • Merck$173

What the payments were for

  • Consulting fees$3,86039%
  • Speaking & faculty fees$4,29043%
  • Food & beverage$1,83018%
  • Education$110%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
United Therapeutics Corporation27$4,699
Johnson & Johnson(2 entities)8$2,996
Bayer5$1,103
Actelion Pharmaceuticals US, Inc.23$1,020
Merck8$173

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,991 in reported general payments places this provider in the 95th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$5,800
Medicare patients
38
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan326$4,105,697
AdempasRiociguat134$1,839,657
Tyvaso DpiTreprostinil57$1,361,979
UptraviSelexipag62$1,298,230
Ambrisentan110$400,668
WinrevairSotatercept-Csrk14$256,081
Tadalafil177$107,171
AdcircaTadalafil14$54,791
Sildenafil Citrate105$38,075
Potassium Chloride50$1,774
Torsemide44$993
Furosemide65$560
Spironolactone21$290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$1,020$5,403,927388 claims
BayerAdempas$1,103$1,839,657134 claims
MerckWinrevair$173$256,08114 claims
United Therapeutics CorporationAdcirca$4,699$54,79114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,080 family providers in New Mexico.

Other family in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →